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Abstract
There is growing interest in the development of novel 
approaches to secondary prevention trials in Alzheimer’s 
disease to facilitate screening and recruitment of research 
participants and to reduce the time and costs associated with 
clinical trials. Several international research collaborations are 
setting up research infrastructures that link existing research 
cohorts, studies or patient registries to establish ‘trial-ready’ 
or ‘readiness’ cohorts. From these cohorts, individuals are 
recruited into clinical trial platforms. In setting up such 
research infrastructures, researchers must make ethically 
challenging design decisions in at least three areas: re-contacting 
participants in existing research studies, obtaining informed 
consent for participation in a readiness cohort, and disclosure 
of Alzheimer’s disease-related biomarkers. These ethical 
considerations have been examined by a dedicated workgroup 
within the European Prevention of Alzheimer’s Dementia 
(EPAD) project, a trans-European longitudinal cohort and 
adaptive proof-of-concept clinical trial platform. This paper 
offers recommendations for the ethical management of 
re-contact, informed consent and risk disclosure which may 
be of value to other research collaborations in the process 
of developing readiness cohorts for prevention trials in 
Alzheimer’s disease and other disease areas.   
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Introduction
  No new drugs for Alzheimer’s disease have become available in over a decade, despite significant research and development efforts 
and a high number of late phase clinical trials (1). This 
failure has been attributed in part to the choice of study 
population (1, 2): while the majority of past research has 
focused on patients with mild-to-moderate Alzheimer’s 
dementia, recent clinical trials have begun to concentrate 
on the earlier stages of the disease identified by revised 
research diagnostic criteria (3, 4). Such studies aim to 
prevent the development or progression of cognitive 
impairment among people who do not show any signs 
of dementia but show biomarker changes thought to be 
associated with increased risk of developing Alzheimer’s 
dementia (5–7).       
Moreover, methodological issues associated with 
the definition of Alzheimer’s Disease itself, study 
recruitment, retention and inter-site variability have been 
identified as barriers to innovation (8–11). Several public-
private research collaborations are currently involved 
in developing new models for conducting clinical trials 
in Alzheimer’s disease. These involve the establishment 
of ‘readiness’ (12) or ‘trial-ready’ cohorts. The primary 
goal of these longitudinal cohorts is to provide 
a well-characterised population of potential research 
participants for recruitment into prevention trials, to 
limit screening failure rates and to reduce recruitment 
time. The readiness cohorts themselves may be drawn 
from existing research registers and cohorts and feed into 
clinical trial ‘platforms’ (13). 
The development of readiness cohorts for clinical 
trial platforms aimed at altering the natural history of 
underlying brain changes associated with Alzheimer’s 
dementia has been described as the ‘pivotal’ (12) element 
in the approach adopted by a growing number of large 
public-private initiatives in Alzheimer’s disease research. 
These include the European Prevention of Alzheimer’s 
Dementia project (EPAD) (12) and the Global Alzheimer’s 
Platform (GAP) (13). A simplified model of the approach 
developed by EPAD and GAP is shown in figure 1. 
Both projects recruit participants from existing registries 
and observational cohorts into a new longitudinal 
cohort study. Participants complete an extensive battery 
of cognitive tests and biological examinations and are 
followed over time. This cohort can then function both 
as a readiness cohort for secondary prevention trials – to 
be run on a clinical trial platform - and as a resource for 
disease modelling. Similar models are being adopted 
within the Dementias Platform UK, and within industry-
sponsored studies (14). 
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The development of linked research infrastructures for 
secondary prevention studies represents an innovative 
approach to drug development for Alzheimer’s disease. 
It also raises distinct ethical questions which recombine 
those traditionally associated with the conduct of cohort 
studies and clinical trials. These questions include 
the recruitment of participants from existing studies, 
ensuring informed consent as participants move through 
the research process, and the disclosure of Alzheimer’s 
dementia risk biomarker status. 
Ethical issues associated with the design and 
development of readiness cohorts 
All medical research requires careful attention to 
ethical values and principles. General guidelines, 
declarations and frameworks exist to guide researchers 
accordingly (15–17). However, the specific concerns 
presented by different types of research conducted in 
different clinical domains may vary significantly. The 
ethical questions associated with research in Alzheimer’s 
dementia have long been primarily concerned with 
the potential risks and burdens of research and the 
capacity of people with dementia to provide informed 
consent (18–23). Since the identification of the ApoE 
susceptibility gene, these concerns has been accompanied 
by debate around the potential psychological impact on 
asymptomatic individuals of learning disease risk (24, 
25). Most recently, specific attention has been paid to 
the issues associated with prevention and biomarker-
led research in ‘preclinical’ populations (26, 27), in 
which biomarker levels presumed to reflect Alzheimer’s 
disease pathology and an assumed increased risk of 
later dementia are present while cognitive functioning 
is normal. These issues revolve around the impact on 
healthy individuals of receiving Alzheimer’s dementia 
risk information associated with a high degree of 
uncertainty and with no clear course of action to reduce 
risk. 
In the following sections we identify three areas that 
require particular attention in the early stages of setting 
up long-term linked research projects involving readiness 
cohorts in Alzheimer’s disease research.  First, we cover 
the recruitment of participants from existing research 
cohorts and registers and the responsibilities of research 
collaborations in this area. Second, we outline ethical 
issues related to informed consent and recruitment into 
multi-stage, linked projects. The third and final area of 
discussion examines particular challenges associated 
with the disclosure of risk status within readiness cohorts 
linked to secondary prevention studies. 
Recruiting from existing studies
Existing registries and longitudinal cohort studies can 
act as resources for the recruitment of well-characterised 
participants for Alzheimer’s disease research (10). 
The identification of eligible individuals or groups of 
participants within existing studies inevitably involves 
some level of screening of existing studies’ data. There 
are two pertinent issues in relation to this process. The 
first relates to how and by whom data is accessed in order 
to re-contact participants. The second relates to the ability 
of studies to re-contact and the procedure for doing so. 
The screening of data from existing studies may be 
undertaken by researchers in the new readiness cohort, 
based on data shared by these existing studies; or it 
may be carried out by the local cohort investigators 
based on selection criteria provided by the readiness 
cohort. If the former approach is adopted, the access, 
use, processing, and sharing of research participants’ 
coded (or identifiable) personal health information and 
research data should adhere to international ethical 
guidelines, including the draft WMA declaration on 
ethical considerations regarding health databases and 
biobanks (28-30). In particular, in any screening process 
researchers must ensure that no personal data is shared 
without participants’ consent. 
In the second case, existing studies can share only 
‘metadata’ which describe the scope (and types) of data 
Figure 1. Simplified model of a readiness cohort drawn from existing studies and leading to one or several clinical trials
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available and the number of people on whom they are 
held. These metadata can be used to establish whether or 
not the original study contains a substantial population 
of eligible participants. In such cases, no individual-
level data are accessed by the new readiness cohort and 
consequently no consent from research participants is 
required. Local cohort investigators can then identify 
participants who meet the inclusion criteria for the 
new study and establish whether they are eligible to be 
re-contacted. 
Approaches to re-contact for research by third 
parties have received comparatively little attention in 
discussions of biomedical research ethics (31), or within 
the governance structures of studies themselves. In 
re-contacting participants, researchers must ensure 
that participants’ autonomy is respected, that their 
privacy is protected and that they are not exposed to 
either unnecessary risks or unacceptable burdens 
through further participation. These principles apply to 
research more generally (15, 32), but may be particularly 
important in a context where individuals are asked to 
extend their existing participation in a new direction. 
Figure 2. Recontact flow chart
Figure 3. The fish trap
The concept of the fish trap has been described in the context of prenatal screening (35, 36) where healthy pregnant women are not confronted with difficult reproductive 
decisions in a single stroke, but progressively, step-by-step. When they first consent to participate in screening, they do not (yet) consent to the steps that may follow - 
amniocentesis or chorionic villus sampling, and eventually termination of the pregnancy. With each step, however, it becomes more difficult to turn back.
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The specific conditions for re-contact for readiness cohort 
should be established through discussions between 
existing studies and their institutional review boards or 
ethics committees. When consent for re-contact is not in 
place, investigators of the original study should first ask 
their participants to consent to being re-contacted about 
further studies. Only those who have consented can then 
be contacted about particular further studies. A decision 
flow for this process is shown in figure 2 below.
If participants are eligible to be re-contacted, 
the investigators of the original study can provide 
information about the new study and ask selected 
participants to contact the investigators of the new study 
if they are interested in taking part. In this approach, 
participants are asked to opt-in to taking part in the new 
study.  
Finally, it is important to recognise that new readiness 
cohorts and other initiatives which draw on existing 
studies have a responsibility to minimise any wider 
negative impact. There is a risk that participation in 
a readiness cohort may increase drop-out rates 
from existing studies, particularly if taking part is a 
comparatively intensive experience. The existence of 
any such effect should be assessed as readiness cohorts 
develop, and researchers should involve working closely 
with investigators and participants in existing studies 
to ensure that the prior commitments and choices of the 
latter are not counteracted or frustrated. This also implies 
that individuals who decide to take part in the new 
readiness cohort should not be excluded from the original 
study through which they are contacted. 
Ensuring informed consent
Readiness cohorts represent one stage on a 
research journey that may start in a clinical registry or 
observational cohort and end with participation in a 
clinical trial. In this respect they differ from traditional 
longitudinal cohorts or traditional clinical trials, as they 
extend over time and encompass various stages in which 
consent may be asked from participants by different 
parties and for different purposes. 
The transitional nature of readiness cohorts presents 
a distinct challenge when it comes to ensuring that 
potential participants are fully informed about the 
scope of the project before consenting to take part. The 
requirement of informed consent aims to ensure that 
research participation is the result of autonomous choice 
(32, 33). Informed consent is given to a specific party 
or person for a specific task or activity, and research 
participants must be made aware of what is involved 
in this task, including the risks, potential benefits and 
burden of participation, and must choose voluntarily to 
take part. However, while full, relevant, and accurate 
information about a research project is indispensable 
(34) in order to give informed consent, this information 
may not be available in readiness cohorts, where the 
various stages of a project are distinct but interconnected, 
and where it is not clear what the final journey of any 
individual participant through the project will be. After 
all, participants in a readiness cohort do not know at 
the outset whether or not they will eventually be asked 
to participate in a clinical trial, and what that trial will 
entail. 
The ethical concern in this context is that by only 
Figure 4. The staged consent model adopted in EPAD
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providing information about the specific activities for 
which informed consent is sought at a particular point 
in time, readiness cohorts would risk becoming ‘fish 
traps’ (35, 36) for their participants (see figure 3). When a 
participant initially consented to take part in the original 
registry or cohort, they did not consent to the tests and 
examinations of the new readiness cohort. Or when a 
participant initially consented to being re-contacted 
about further research studies, they did not consent 
to undergoing a lumbar puncture as part of the new 
readiness cohort, to learning about their Alzheimer’s 
disease risk, or taking drugs in the context of a clinical 
trial. With each step, the burdens and risks of research 
participation will accumulate incrementally. At the 
same time, once started on the path of participation, it 
may become progressively more difficult to withdraw. 
This ‘luring’ or ‘easing’ of participants into clinical trial 
participation would be a form of misleading or deceiving 
participants, which would run counter to the ethical 
requirement of informed consent.  It may also increase 
the risk of drop-out, jeopardising the scientific integrity 
of the data for the purpose of natural disease course 
monitoring by introducing additional bias.
In order to prevent a fish trap, global information 
about the whole study trajectory must be available to 
potential participants from the outset. A staged model 
for informed consent (37) should present information 
about the entire study journey to research participants 
at every step. Informed consent requires information 
specific to the stage for which consent is sought. At each 
step of the way, however, participants should also be 
informed about further stages of the research project and 
the project in its entirety.  A staged consent approach 
allows for study information to be repeated, rehearsed 
and built upon and for participants to be reminded that 
they are able to withdraw at any time without having 
to give any reasons. Without this general information, 
consent would not be informed consent. A simplified 
version of the staged model for informed consent that 
was adopted in EPAD is shown in figure 4 below.
Education and risk disclosure 
A core ethical consideration associated with 
secondary prevention research in Alzheimer’s disease 
relates to the potential impact on research participants 
of learning that one is at elevated risk of developing 
Alzheimer’s dementia, based on either ApoE genotype 
or other biomarkers, such as beta-amyloid status (26, 
38).  Concerns about disclosure of ApoE (39) and 
amyloid status (40, 41) revolve around the potential 
the psychological, behavioural and social harms of 
disclosure, particularly of amyloid status (42). 
In the case of readiness cohort, decisions about 
whether or not to disclose risk information are 
encountered at three stages: during contact to take part 
in a readiness cohort; following cohort examinations 
and assessments; and as part of the recruitment from 
readiness cohorts into clinical trials.  At each stage, the 
pros and cons of disclosure differ. 
At the first stage, that of contact to take part in 
the readiness cohort, the decision over whether or 
not to disclose risk status is shaped by the proposed 
constituency of the readiness cohort. If a readiness 
cohort aims to recruit only a population thought to be 
at increased risk of developing Alzheimer’s dementia, 
disclosure is essential in order to make individuals aware 
why they are considered eligible for the research – a 
well-established research-ethical requirement (32).  If, in 
contrast, the readiness cohort includes a wide range 
of risk states and researchers are blinded to why any 
individual is contacted, it is no longer clear why any 
individual participant has been contacted. However, the 
inclusion of ‘lower risk’ participants should not occur 
solely as a means of avoiding disclosure, not least because 
these participants would be subjected to potentially 
unnecessary risks and burdens as a consequence. 
At the second stage, guidance frameworks for 
population-based research suggest that individual 
research results should be returned if consent is in place, 
if the findings are analytically valid, if they reveal a 
significant risk of a serious health condition, and 
finally if they are actionable (43).  Neither ApoE nor 
amyloid information has confirmed clinical utility and 
robust information about likely disease progression in 
individuals does not yet exist (44).  However, this may 
be changing (45) and indeed risk information may be of 
value to research participants regardless of the lack of 
effective treatments (46).  
Finally, ApoE and amyloid status should be disclosed 
as part of a transparent enrolment process to secondary 
prevention clinical trials (47), as is the case in a number of 
ongoing studies (26, 48, 49). This reflects the requirement 
to make individuals aware of why they are considered 
eligible for research. As such, participants in readiness 
cohorts should be informed on what basis they are 
contacted for any clinical trial. However, there are 
important features of this process which differ from 
conventional clinical trial structures. 
Within recruitment to conventional trial structures, 
participants can be provided with information at the 
point of screening for the study to enable them to decide 
whether or not risk information is something they would 
like to know (48, 50). In the context of readiness cohorts, 
participants are enrolled at a stage when it is not yet 
known whether or not they will participate in a trial 
or for what reasons (i.e. based on what biomarkers) 
they may be recruited. However, because participants 
are aware that the cohort exists to facilitate trials in 
preclinical/at-risk and prodromal Alzheimer’s disease 
populations, being invited to take part in a trial 
necessarily constitutes disclosure of preclinical/at-risk or 
prodromal status. To choose not to know this information 
would be to choose not to be contacted for a trial, which 
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is incompatible with the primary goal of a readiness 
cohort. 
The complexities associated with disclosing risk status 
within linked research structures prompt three core 
recommendations for establishing readiness cohorts.
Firstly, all participants entering readiness cohorts 
should be willing to learn biomarker results related 
to their risk of developing Alzheimer’s dementia and 
understand the uncertainty of that evidence, as there is 
no effective way of protecting an individual’s right not 
to know (this information) while preserving transparent 
enrolment procedures. 
Secondly, even if no return of individual research 
results will occur during the cohort stage of research, 
the link to secondary prevention studies means that 
all potential participants should receive educational 
materials and/or briefings about risk information during 
the cohort consent process. This ensures that potential 
participants are informed about what biomarkers can 
and cannot tell them about their risk of developing 
Alzheimer’s dementia, and allows them to make an 
informed decision about whether this is information they 
would like to learn in the future. 
Finally, readiness cohort researchers should work with 
trial sponsors to ensure that the disclosure of biomarker 
information from cohort examinations is carried out by 
appropriately qualified professionals.
Conclusion
The development of linked projects for Alzheimer’s 
disease research, which draw on existing research studies 
to establish readiness cohorts for secondary prevention 
clinical trials, raises distinct ethical challenges. These 
derive from the novelty of the approach and how it 
combines and reframes existing issues of concern. 
Particular ethical considerations and challenges revolve 
around the process of identifying and contacting 
potential participants in the readiness cohort; the 
staged provision of specific and general information to 
research participants in order to prevent them entering 
a ‘fish trap’, and the establishment of robust procedures 
for informing participants about the meaning of risk 
information and for disclosing risk. Recommendations in 
these areas are summarised in Box 1. 
The concerns and recommendations detailed here 
suggest that it is critically important that researchers 
consider the journey of a research participant through 
the various stages of the research project from start to 
finish, from re-contact to clinical trial participation. This 
includes considering how challenges associated with later 
stages of research, such as recruitment from a readiness 
cohort into a clinical trial which may involve risk 
disclosure, affect the information that should be provided 
to participants during initial recruitment into the cohort. 
It is critical to the success of readiness cohorts, however, 
to carefully align re-contact, informed consent and risk 
disclosure processes throughout the research project.
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